Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer

Breast Cancer Research

Volumn 8, Issue 3, 2006, Pages

  Burcombe, Russell ^a   Wilson, George D ^b   Dowsett, Mitch ^c   Khan, Ifty ^d   Richman, Paul I ^e   Daley, Frances ^b   Detre, Simone ^c   Makris, Andreas ^e  

^a MAIDSTONE HOSPITAL   (United Kingdom)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EVIDENCE BASED MEDICINE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MEDICAL DECISION MAKING; PREDICTION; PROSPECTIVE STUDY; RELIABILITY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VALIDATION STUDY; ADJUVANT THERAPY; BREAST NEOPLASMS; EVALUATION STUDY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33745441204     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1508     Document Type: Article

References (45)

1. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998, 9:1179-1184.
2. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
4. Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ: Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 2005, 16:267-272.
5. Gasparini G, Boracchi P, Verderio P, Bevilacqua P: Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994, 57:822-829.
6. Dawson AE, Norton JA, Weinberg DS: Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol 1990, 136:1115-1124.
7. Vielh P, Chevillard S, Mosseri V, Donatini B, Magdelenat H: Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am J Clin Pathol 1990, 94:681-686.
8. Mainwaring PN, Ellis PA, Detre S, Smith IE, Dowsett M: Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer. J Clin Pathol 1998, 51:34-37.
9. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977, 39:1289-1294.
10. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995, 180:297-306.
11. Akashi-Tanaka S, Tsuda H, Fukuda H, Watanabe T, Fukutomi T: Prognostic value of histopathological therapeutic effects and mitotic index in locally advanced breast cancers after neoadjuvant chemotherapy. Jpn J Clin Oncol 1996, 26:201-206.
12. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993, 16:223-228.
13. Honkoop AH, Pinedo HM, De Jong JS, Verheul HM, Linn SC, Hoekman K, Wagstaff J, van Diest PJ: Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997, 107:211-218.
14. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, et al.: Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998, 4:230-236.
15. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20:1456-1466.
16. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD: Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005, 92:147-155.
17. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996, 2:585-592.
18. Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa AP, Calderini P, Liscia DS: Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer 1993, 29A:1509-1513.
19. Gottardi O, Tabiadon D, Scanzi F, Bono A, Majno M, Ferrari M, Colombo P: Clinical and prognostic usefulness of Ki67 determination in breast carcinoma. Pathologica 1992, 84:15-22.
20. Lee AK, Loda M, Mackarem G, Bosari S, DeLellis RA, Heatley GJ, Hughes K: Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a, bNOMO): clinicopathologic features and outcome. Cancer 1997, 79:761-771.
21. Pierga JY, Leroyer A, Viehl P, Mosseri V, Chevillard S, Magdelenat H: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 1996, 37:57-64.
22. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW, Ellis IO: Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995, 71:146-149.
23. Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K, Nordling S: Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 1997, 36:369-374.
24. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, von Smitten K: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 1993, 68:579-583.
25. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer 1993, 71:3926-3931.
26. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991, 67:421-428.
27. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995, 72:1259-1266.
28. Daidone MG, Luisi A, Martelli G, Benini E, Veneroni S, Tomasic G, De Palo G, Silvestrini R: Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br J Cancer 2000, 82:270-277.
29. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998, 16:470-479.
30. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, et al.: Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001, 85:1106-1112.
31. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 1993, 67:606-611.
32. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pl. Br J Cancer 1996, 74:1458-1465.
33. Rudas M, Gnant MF, Mittlbock M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A: Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 1994, 32:165-175.
34. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F, Bolsi G, Bertoli G, Alquati P, Dogliotti L: Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 1996, 16:3105-3110.
35. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998, 48:107-116.
36. Dardes RD, Horiguchi J, Jordan VC: A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer. Int J Oncol 2000, 16:25-30.
37. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 1998, 48:11-20.
38. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999, 17:3058-3063.
39. Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T, Skoog L: Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol 1999, 38:597-601.
40. Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M: Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 1999, 53:51-59.
41. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998, 77:621-626.
42. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165-4174.
43. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, et al.: Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003, 9:33-41.
44. Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, et al.: Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000, 6:4610-4617.
45. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000, 89:2145-2152.